Analyzing Profusa (PFSA) and Its Peers

Profusa (NASDAQ:PFSA) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its competitors? We will compare Profusa to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Insider and Institutional Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 19.9% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Profusa and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	79	80	160	7	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.45%. Given Profusa’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its competitors.

Risk and Volatility

Profusa has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Profusa’s competitors have a beta of 1.80, meaning that their average stock price is 80% more volatile than the S&P 500.

Profitability

This table compares Profusa and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-570.12%	-123.56%	-53.83%

Valuation and Earnings

This table compares Profusa and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.01
Profusa Competitors	$61.66 million	-$32.64 million	5.35

Profusa’s competitors have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Profusa competitors beat Profusa on 10 of the 13 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.